Clinical Report: Incidence of Cataract Surgery in Patients Treated with Mirvetuximab Soravtansine

Overview

This study evaluates the incidence of cataract surgery in patients treated with mirvetuximab soravtansine (MIRV) for recurrent ovarian cancer, using a matched cohort design. The findings indicate a significantly higher rate of cataract surgery among MIRV-treated patients compared to those not exposed to the drug.

Background

Mirvetuximab soravtansine is an antibody-drug conjugate used in the treatment of ovarian cancer, known for its ocular toxic effects, including keratopathy, blurry vision, and dry eyes. While short-term effects are documented, the long-term risk of cataracts remains less understood. Understanding the incidence of cataracts in this patient population is crucial for informing treatment decisions and patient management.

Data Highlights

• MIRV Exposed: 42.3% (22 of 52)
• Non-Exposed: 11.5% (6 of 52)

Key Findings

• Cataract surgery was performed in 42.3% of patients exposed to MIRV compared to 11.5% in non-exposed patients (aOR 12.61, P < .001), indicating a significant increase in risk.
• Adding one treatment cycle of MIRV increased the odds of cataract surgery (aOR 1.21, P = .01).
• 64% of patients treated with MIRV for 6 or more months underwent cataract surgery.
• Patients requiring cataract surgery had higher rates of keratopathy, blurry vision, and dry eyes.
• The median time from MIRV initiation to cataract surgery was 17.54 months.

Clinical Implications

Healthcare providers should monitor patients receiving MIRV for potential long-term ocular toxic effects, including cataract formation. Proactive management strategies, including regular ophthalmic evaluations, may be necessary to address these risks effectively, such as scheduling eye exams every 3-6 months during treatment.

Conclusion

The study highlights a concerning incidence of cataract surgery among patients treated with MIRV, suggesting the need for ongoing surveillance of ocular safety in this population, particularly in light of existing literature that may underreport such risks.

Related Resources & Content

1. The ASCO Post, FDA Approves Mirvetuximab Soravtansine-gynx for FRα-Positive, Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
2. The ASCO Post, Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer
3. The ASCO Post, Patient-Reported Outcomes With Mirvetuximab Soravtansine vs Chemotherapy in FRα-Positive, Platinum-Resistant Ovarian Cancer
4. The ASCO Post, Mirvetuximab Soravtansine for FRɑ-Positive, Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer
5. Elahere, FDA Drug Label
6. Mirvetuximab Soravtansine Overview
7. Incidence and clinical features of cataracts with mirvetuximab soravtansine